Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine Peng X; Chen B; Lim CC; Sawyer DBMol Interv 2005[Jun]; 5 (3): 163-71Anthracyclines remain a mainstay of chemotherapy in spite of their well-recognized cardiotoxicity. Recent experience with trastuzumab (Herceptin) and anthracycline therapy has prompted a detailed analysis of the function of erbB2 in the heart. These studies demonstrate a cardioprotective effect of neuregulin, the endogenous ligand for the erbB4/erbB2 heterodimeric receptor complex. Although the mechanisms of cytoprotection remain incompletely understood, these studies have triggered the question of whether physiological manipulation of cardioprotective pathways that involve erbB can be used to improve outcome in patients treated with anthracyclines. The local activation of cardioprotection by cardiovascular exercise may be such a manipulation and warrants further investigation.|*Preventive Medicine[MESH]|Animals[MESH]|Anthracyclines/*toxicity[MESH]|Antibiotics, Antineoplastic/*toxicity[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/pharmacology[MESH]|Antineoplastic Agents/pharmacology[MESH]|Heart/*drug effects[MESH]|Humans[MESH]|Trastuzumab[MESH] |